• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

无低白蛋白血症的肾病性蛋白尿:临床特征及对血管紧张素转换酶抑制剂的反应

Nephrotic proteinuria without hypoalbuminemia: clinical characteristics and response to angiotensin-converting enzyme inhibition.

作者信息

Praga M, Borstein B, Andres A, Arenas J, Oliet A, Montoyo C, Ruilope L M, Rodicio J L

机构信息

Department of Nephrology, Hospital 12 de Octubre, Madrid, Spain.

出版信息

Am J Kidney Dis. 1991 Mar;17(3):330-8. doi: 10.1016/s0272-6386(12)80483-5.

DOI:10.1016/s0272-6386(12)80483-5
PMID:1996578
Abstract

Although hypoalbuminemia is a fundamental characteristic of nephrotic syndrome (NS), there are many patients with massive proteinuria that do not develop hypoalbuminemia. We have studied the clinical and biochemical characteristics of 19 patients with persistent massive proteinuria (greater than 5 g/d) and normal serum albumin (group I) in comparison with 16 patients with similar proteinuria excretion, but persistent hypoalbuminemia (group II). Most of group I patients had diagnoses suggesting glomerular hyperfiltration (focal glomerulosclerosis [FGS] associated with vesicoureteral reflux [VUR], reduction of renal mass, proteinuria associated with obesity, sclerotic phase of idiopathic crescentic glomerulonephritis [GN] in contrast with those of group II, in which membranous GN was the most frequent diagnosis. We prospectively investigated differences in the antiproteinuric effect of captopril, an antiotensin-converting enzyme inhibitor (ACEI); after 6 months of treatment, proteinuria decreased clearly in group I (7.1 +/- 1.7 to 3.7 +/- 1.7 g/d; P less than 0.001), whereas no significant changes were observed in group II (8.1 +/- 2.4 to 8.8 +/- 4 g/d). Serum creatinine (Scr) remained stable during captopril treatment in group I, whereas three patients in group II showed a worsening of renal function.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

虽然低白蛋白血症是肾病综合征(NS)的一个基本特征,但有许多大量蛋白尿患者并未出现低白蛋白血症。我们研究了19例持续性大量蛋白尿(大于5g/d)且血清白蛋白正常的患者(第一组)的临床和生化特征,并与16例蛋白尿排泄量相似但持续性低白蛋白血症的患者(第二组)进行了比较。与第二组相比,第一组的大多数患者诊断提示肾小球高滤过(局灶节段性肾小球硬化[FGS]伴膀胱输尿管反流[VUR]、肾实质减少、肥胖相关性蛋白尿、特发性新月体性肾小球肾炎[GN]硬化期),第二组中膜性GN是最常见的诊断。我们前瞻性地研究了抗高血压转换酶抑制剂(ACEI)卡托普利的抗蛋白尿作用差异;治疗6个月后,第一组蛋白尿明显下降(从7.1±1.7降至3.7±1.7g/d;P<0.001),而第二组未观察到显著变化(从8.1±2.4升至8.8±4g/d)。第一组卡托普利治疗期间血清肌酐(Scr)保持稳定,而第二组有3例患者肾功能恶化。(摘要截短于250字)

相似文献

1
Nephrotic proteinuria without hypoalbuminemia: clinical characteristics and response to angiotensin-converting enzyme inhibition.无低白蛋白血症的肾病性蛋白尿:临床特征及对血管紧张素转换酶抑制剂的反应
Am J Kidney Dis. 1991 Mar;17(3):330-8. doi: 10.1016/s0272-6386(12)80483-5.
2
Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria.血管紧张素转换酶抑制对肾病性蛋白尿患者的长期有益作用。
Am J Kidney Dis. 1992 Sep;20(3):240-8. doi: 10.1016/s0272-6386(12)80696-2.
3
Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration.继发于超滤的局灶节段性肾小球硬化症中,尽管存在大量蛋白尿,但无低白蛋白血症。
Am J Kidney Dis. 1999 Jan;33(1):52-8. doi: 10.1016/s0272-6386(99)70257-x.
4
Antiproteinuric effect of angiotensin-converting-enzyme inhibitors in patients with primary glomerular disease and normal renal function.血管紧张素转换酶抑制剂对原发性肾小球疾病且肾功能正常患者的降蛋白尿作用。
Nephrol Dial Transplant. 1990;5 Suppl 1:81-3. doi: 10.1093/ndt/5.suppl_1.81.
5
Efficacy of captopril treatment in children with steroid-resistant nephrotic syndrome.卡托普利治疗儿童激素抵抗型肾病综合征的疗效
Acta Paediatr Jpn. 1994 Dec;36(6):658-61. doi: 10.1111/j.1442-200x.1994.tb03264.x.
6
ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome.血管紧张素转换酶抑制剂可改善特发性膜性肾病和持续性肾病综合征患者的肾小球大小选择性。
Am J Kidney Dis. 2000 Mar;35(3):381-91. doi: 10.1016/s0272-6386(00)70190-9.
7
Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study.1型糖尿病患者肾病综合征的缓解:卡托普利研究中患者的长期随访
Am J Kidney Dis. 1999 Aug;34(2):308-14. doi: 10.1016/s0272-6386(99)70360-4.
8
Low-dose angiotensin-converting-enzyme inhibitor captopril to reduce proteinuria in adult idiopathic membranous nephropathy: a prospective study of long-term treatment.
Nephrol Dial Transplant. 1995;10(1):25-9.
9
Glomerular abundance of nephrin and podocin in experimental nephrotic syndrome: different effects of antiproteinuric therapies.实验性肾病综合征中肾小球nephrin和足突蛋白的丰度:抗蛋白尿疗法的不同作用
Am J Physiol Renal Physiol. 2005 Oct;289(4):F880-90. doi: 10.1152/ajprenal.00451.2004. Epub 2005 Jun 7.
10
The progression of adriamycin-induced nephrotic syndrome in rats and the effect of captopril.阿霉素诱导的大鼠肾病综合征的进展及卡托普利的作用
Toxicol Appl Pharmacol. 1986 Jan;82(1):164-74. doi: 10.1016/0041-008x(86)90448-5.

引用本文的文献

1
Comparison and prognostic analysis of focal segmental glomerulosclerosis patients with or without nephrotic syndrome at onset.发病时伴有或不伴有肾病综合征的局灶节段性肾小球硬化患者的比较及预后分析。
BMC Nephrol. 2025 Jul 5;26(1):353. doi: 10.1186/s12882-025-04292-z.
2
Glomerular diameter is associated with a reduction in urinary protein by treatment with dapagliflozin in patients with chronic kidney disease.在慢性肾脏病患者中,肾小球直径与使用达格列净治疗后尿蛋白减少有关。
Clin Exp Nephrol. 2025 Jan 20. doi: 10.1007/s10157-025-02625-8.
3
Comparing Long-Term Outcomes in Glomerular Disease Patients Presenting with Nephrotic Syndrome Versus Nephrotic Range Proteinuria.
比较肾病综合征与肾病范围蛋白尿的肾小球疾病患者的长期预后。
Life (Basel). 2024 Dec 18;14(12):1674. doi: 10.3390/life14121674.
4
Clinical characteristics and treatment compounds of obesity-related kidney injury.肥胖相关性肾损伤的临床特征及治疗药物
World J Diabetes. 2024 Jun 15;15(6):1091-1110. doi: 10.4239/wjd.v15.i6.1091.
5
Treatment of membranous nephropathy: Perspectives on current and future therapies.膜性肾病的治疗:当前及未来治疗方法的展望
Front Nephrol. 2023 Jan 27;3:1110355. doi: 10.3389/fneph.2023.1110355. eCollection 2023.
6
Glomerular hyperfiltration and hypertrophy: an evaluation of maximum values in pathological indicators to discriminate "diseased" from "normal".肾小球高滤过和肥大:对病理指标最大值的评估,以区分“患病”与“正常”。
Front Med (Lausanne). 2023 Jul 13;10:1179834. doi: 10.3389/fmed.2023.1179834. eCollection 2023.
7
Nephrotic Syndrome Complications - New and Old. Part 1.肾病综合征并发症——新与旧。第1部分。
Maedica (Bucur). 2022 Mar;17(1):153-168. doi: 10.26574/maedica.2022.17.1.153.
8
The difference between patients with nephrotic syndrome and nephrotic-range proteinuria in IgA nephropathy: a propensity score matched cohort study.IgA 肾病中肾病综合征与肾病范围蛋白尿患者的差异:一项倾向评分匹配队列研究。
BMC Nephrol. 2022 Apr 29;23(1):163. doi: 10.1186/s12882-022-02799-3.
9
Therapeutic trials in adult FSGS: lessons learned and the road forward.成人 FSGS 的治疗试验:经验教训与前进道路。
Nat Rev Nephrol. 2021 Sep;17(9):619-630. doi: 10.1038/s41581-021-00427-1. Epub 2021 May 20.
10
Glomerular Diseases in Diabetic Patients: Implications for Diagnosis and Management.糖尿病患者的肾小球疾病:对诊断和管理的启示
J Clin Med. 2021 Apr 24;10(9):1855. doi: 10.3390/jcm10091855.